Genenta Science Reports TEM-GBM Study Update, 44% 18-Month Survival Rate Achieved
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 24 2025
0mins
Source: Newsfilter
- Study Progress: As of November 21, 2025, Genenta Science has treated 25 patients with Temferon in newly diagnosed glioblastoma multiforme cases.
- Survival Rate Improvement: The 18-month survival rate increased from 38% in April 2025 to 44%, indicating enhanced treatment efficacy.
- Long-Term Survival Case: The first patient in the study survived 39 months post-Temferon treatment without additional therapies.
- Financial Position: As of November 1, 2025, the company holds approximately $30 million in cash and short-term investments to support ongoing research.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like GNTA with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on GNTA
Wall Street analysts forecast GNTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GNTA is 7.00 USD with a low forecast of 7.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.350
Low
7.00
Averages
7.00
High
7.00
Current: 1.350
Low
7.00
Averages
7.00
High
7.00
No data
About GNTA
Genenta Science SpA is an Italy-based company engaged in clinical-stage biotechnology research. The Company focuses on the development of lentivirus-based gene and cell therapies in cancer. It uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The Company not only operates locally but also is present in global markets, including the United States.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Genenta Science Transitions to Defense Sector Consolidator
- Strategic Shift: Genenta Science announced its rebranding to Saentra Forge S.p.A. and plans to acquire privately held businesses with approximately €5 million in EBITDA, marking a strategic pivot towards the defense sector.
- Funding Commitment: The company has entered into an agreement to provide €5.1 million in funding to ATC, which is projected to achieve around €4 million in revenue by 2026 and double its EBITDA by 2027, highlighting the growth potential of this new direction.
- Clinical Milestones: Genenta has reached key clinical milestones aimed at establishing partnerships with major pharmaceutical and biotech firms to accelerate development, improve market access, and enhance strategic value.
- Financial Outlook: Despite a 68.29% decline in stock over the past year, shares are currently trading 87.5% above the 20-day simple moving average, indicating short-term strength, with expectations of cash and equivalents reaching approximately $33 million by the end of 2025.
Continue Reading
Biomx Inc Shares Surge After 13D Filing Reveals Major Stake
- Stake Increase: Pyu Pyu Capital disclosed a 19.99% stake in Biomx Inc through a 13D filing, causing the company's shares to surge 103.4% to $8.34 in pre-market trading, indicating strong market confidence in its future prospects.
- Market Reaction: The dramatic rise in Biomx Inc's stock price reflects optimistic investor expectations regarding its potential growth opportunities, particularly in the context of strategic transformations within the biotechnology sector, which may attract further investor interest.
- Industry Impact: The significant increase in Biomx Inc's stock price could positively influence other biotechnology companies, enhancing overall market confidence in the sector and potentially leading to increased capital inflows into related fields.
- Investor Sentiment: This substantial stock price increase not only elevates Biomx Inc's market position but may also encourage other companies to adopt similar strategic initiatives to attract investors and enhance their competitive edge.
Continue Reading